Adherence and Persistence Rates Highest Among Psoriasis and Psoriatic Arthritis Treated With Guselkumab and Ustekinumab

Psoriasis and psoriatic arthritis (PsA) patient adherence and persistence was highest among those treated with guselkumab (GUS) and ustekinumab (UST), followed by secukinumab (SEC), ixekizumab (IXE), adalimumab (ADA), etanercept (ETA), and certolizumab pegol (CER). The results of a review were published in Journal of Dermatological Treatment.

“We examined adherence and persistence among patients [with psoriasis and] with comorbid PsA who initiated treatment with any of these biologics,” wrote the study authors.

Researchers studied seven study cohorts during fixed follow-up periods (3, 6, 9, and 12 months), looking at adherence and persistence rates during these periods. Participants in the study were adult patients with at least 1 pharmacy/medical claim for any of the seven biologics (ADA, CER, ETA, GUS, IXE, SEC, and UST).

During the 9-month follow-up period, adherence rates were highest among those treated with GUS (59.5%) and UST (57.0%), followed by SEC (47.9%), IXE (47.6%), ADA (46.8%), ETA (37.4%), and CER (22.0%). Persistence rates were also numerically highest among those treated with GUS (65.9%) and UST (65.7%).

“Adherence and persistence rates were numerically highest among patients who initiated GUS and UST,” concluded the study authors.

Reference
Xu C, Teeple A, Wu B, Fitzgerald T, Feldman SR. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population. J Dermatolog Treat. Published July 15, 2021. doi:10.1080/09546634.2021.1950600